The role of aspirin in cardiovascular diseases--forgotten benefits?
Related Experiment Video
Updated: Aug 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Adam Williams1, Charles H Hennekens
1University of Miami School of Medicine, Miami, FL, USA.
Insights
Widespread aspirin use is crucial for preventing cardiovascular events. Appropriate aspirin use in secondary and primary prevention can significantly reduce premature deaths and myocardial infarctions (MIs).
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Background:
- Cardiovascular diseases (CVDs) pose a significant global health burden.
- There is a recognized need to optimize the use of aspirin for preventing vascular events.
Purpose of the Study:
- To emphasize the importance of expanded and appropriate aspirin utilization in secondary and primary cardiovascular prevention.
- To highlight aspirin's role in managing acute myocardial infarction (MI) and occlusive stroke.
Main Methods:
- Review and synthesis of existing evidence on aspirin's efficacy in secondary and primary prevention.
- Analysis of risk stratification for primary prevention, focusing on 10-year coronary event risk.
Main Results:
- Aspirin is recommended for patients with prior occlusive vascular events and acute MI or stroke.
- Aspirin should be considered for primary prevention in individuals with a 10-year coronary event risk of 10% or higher.
Conclusions:
- Increased and appropriate aspirin use can avert numerous premature deaths from secondary prevention.
- Wider aspirin application can prevent myocardial infarctions in primary prevention strategies.
Abstract:
The increasing burden of cardiovascular diseases in developed, as well as developing countries, underscores the need for the more widespread and appropriate use of aspirin in secondary prevention of occlusive vascular events during acute evolving myocardial infarction (MI) and in primary prevention. Aspirin should be far more widely used in a wide range of patients who have suffered a prior occlusive vascular event and in all patients suffering acute MI or occlusive stroke. Finally, in primary prevention, aspirin should be considered for individuals whose 10-year risks of a coronary event are > or = 10%, as an adjunct not alternative to the management of other risk factors. The more widespread and appropriate use of aspirin will avoid many premature deaths in secondary prevention and MIs in primary prevention.
More Related Videos
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

